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Abstract
The aim of this study was to reveal the clinical features of anterior urethral recurrence in pa-
tients with superficial bladder cancer, and to determine the appropriate treatment. Three hundred
and three patients with superficial bladder cancer, who were newly diagnosed and initially treated
conservatively in our hospital between 1965 and 1990, were followed for at least 5 years and their
clinical outcomes were analyzed. Clinical factors, including anterior urethral recurrence, were
evaluated statistically regarding tumor progression. Eight patients (2.6%) had anterior urethral re-
currence following superficial bladder cancer. Twenty-four patients (7.9%) had tumor progression
and 149 (49.2%) had tumor recurrence. In a multivariate analysis using a logistic model, anterior
urethral recurrence was the most important factor, followed by histological grade. Four of 5 pa-
tients who were treated for anterior urethral recurrent tumors by transurethral resection showed
progression and died of the cancer within one year. Two of the remaining three patients who un-
derwent radical cysto-urethrectomy at the time of anterior urethral recurrence survived. Anterior
urethral recurrence following superficial bladder cancer is a predictor for rapid subsequent malig-
nant progression. Once there is anterior urethral recurrence, radical intensive therapy, including
radical cysto-urethrectomy, should be carried out immediately.
KEYWORDS: superficial bladder cancer, anterior urehral recurrence, prognosis, predictor
∗PMID: 14726966 [PubMed - indexed for MEDLINE]
Copyright (C) OKAYAMA UNIVERSITY MEDICAL SCHOOL
 Anterior Urethral Recurrence of Superﬁcial Bladder Cancer: Its Clinical Signiﬁcance
 
Takashi Saika?, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,
Haruki Kaku, Naoki Akebi, Nobuyuki Kusaka, and Hiromi Kumon
 
Department of Urology, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan
 
The aim of this study was to reveal the clinical features of anterior urethral recurrence in patients with superﬁcial bladder cancer, and to determine the appropriate treatment. Three hundred and three patients with superﬁcial bladder cancer, who were newly diagnosed and initially treated conservatively in our hospital between 1965 and 1990, were followed for at least 5 years and their clinical outcomes were analyzed. Clinical factors, including anterior urethral recurrence, were evaluated statistically regarding tumor progression. Eight patients (2.6 ) had anterior urethral recurrence following superﬁcial bladder cancer. Twenty-four patients(7.9 )had tumor progression and 149 (49.2 )had tumor recurrence. In a multivariate analysis using a logistic model, anterior urethral recurrence was the most important factor, followed by histological grade. Four of 5 patients who were treated for anterior urethral recurrent tumors by transurethral resection showed progression and died of the cancer within one year. Two of the remaining three patients who underwent radical cysto-urethrectomy at the time of anterior urethral recurrence survived.
Anterior urethral recurrence following superﬁcial bladder cancer is a predictor for rapid subsequent malignant progression. Once there is anterior urethral recurrence, radical intensive therapy,
including radical cysto-urethrectomy, should be carried out immediately.
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C linical problems associated with superﬁcial bladder cancer are local recurrence and progression to the advanced stage. Superﬁcial bladder cancer itself is not a life-threatening disorder, provided it remains within the bladder mucosa. Once this type of cancer progresses to local muscle invasion or metastasis, anticancer manage-
ment strategies such as radical surgery, systemic chemo-
therapy, or radiation therapy may have little eﬀect, and the prognosis may be poor. Therefore, prediction of
 
progression is a major issue in the clinical management of superﬁcial bladder cancer. While numerous markers used to analyze the prognostic factors of superﬁcial bladder cancer have been reported［1-6］, anterior urethral recur-
rence of superﬁcial bladder cancer has not been discussed as one of these prognostic factors, thus prompting our evaluation.
Materials and Methods
 
We statistically analyzed factors aﬀecting progression in patients with superﬁcial bladder cancer. From 1965 to 1990, 384 patients with superﬁcial bladder transitional
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carcinoma(without concomitant carcinoma in situ;CIS)
were newly diagnosed in our hospital. Among these 303,
those who received conservative transurethral resection
(TUR)and were followed for at least 5 years or until death, were evaluated in this study. Eighty-one patients were excluded from the analysis, since they underwent incomplete initial treatment or dropped out of follow-up treatment. In this study, malignant progression was deﬁned as a local invasion over the muscle layer, lymph node metastasis, or distant metastasis. There were 257 male and 46 female patients whose age ranged from 19 to 88;the mean age was 61.4. The mean period of follow-
up for patients was 84.0 months, ranging from 30 to 330 months. The patients were followed as described;cystos-
copy was performed every 3 months for 2 years after TUR, then every 4 months from 2 to 3 years, every 6 months from 3 to 5 years, and annually after 5 years.
Urine cytology was examined at the time of cystoscopy.
Intravenous pyelography, pelvic computed tomography
(CT), and chest radiography were performed annually.
For the statistical analysis of the factors at the time of initial treatment, uni-variate and multi-variate analyses by Cox’s proportional Hazards model were performed. The factors and the categories of statistical analysis were age,
sex, clinical symptoms, number of tumors, tumor size,
tumor shape, tumor involvement of the bladder neck,
stage based on UICC 1997, and grade(highest grade in cases involving multiple grades). In 149 patients with tumor recurrence, factors related to tumor progression were analyzed using a logistic model. A P value of less than 0.05 was considered statistically signiﬁcant in the uni-variate analysis.
The clinical outcomes of patients with anterior urethral recurrence of superﬁcial bladder cancer were also anal-
yzed. A total of 8 patients suﬀered from anterior urethral recurrence during this period. In this study, anterior urethral recurrence was deﬁned as follows:tumor recur-
rence at the anterior urethra excluding the prostatic urethra and bladder neck in males, and tumor recurrence at the urethra excluding the bladder neck in females.
Results
 
During the follow up period, there were recurrences in 149 patients and among these, there was progression in 24 patients. These recurrent cases were analyzed accord-
ing to the factors and categories shown in Table 1. The factors were evaluated in terms of their impact on
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Urethral Tumor(＋) 0  4(18.7%) 0  1(0.8%)
Tumor No.
1  13  5  51  20 2-4  6  6  38  38 5 or more  5(20.8%) 13(54.2%) 36(28.8%) 67(53.6%)
Tumor Size
＜1 cm  4  3  21  14 1-3 cm  16(66.7%) 16(66.7%) 73(58.4%) 75(60.0%)
3 cm＜ 4(16.7%) 5(20.8%) 31(24.8%) 36(28.8%)
Tumor Shape Pap. Stalk  10  5  84  55 Pap. Broadbased  7(29.2%) 12(50.0%) 29 (23.2%) 55(44.0%)
Non-Pap. 7(29.2%) 7(29.2%) 12( 9.6%) 15(12.0%)
Neck Tumor(＋) 7(29.2%) 15(62.5%) 39 (31.2%) 71(56.8%)
Stage Ta  7  4  63  55 T1  17(70.8%) 20(83.3%) 61(48.8%) 70(56%)
Unknown  1  0 Grade G1  3  0  36  26 G2  16  14  75  78 G3  4(16.7%) 10(41.7%) 11(8.8%) 21(16.8%)
Unknown  1  3  0
?Worst feature among the factors at each recurrence without progression.
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malignant progression. In the uni-variate analysis, ante-
rior urethral recurrence, and tumor shape, grade, and stage all had a statistically signiﬁcant correlation with progression. In the multivariate analysis using a logistic model, anterior urethral recurrence was the most impor-
tant predictor of progression, followed by histological grade(Table 2). There was anterior urethral recurrence in 8 patients at 14 to 148 months (median:47.5)after the initial diagnosis, with no obvious sub-mucosal invasion apparent upon pre-operatural examinations such as ureth-
roscopy and CT. All of these patients had concomitant bladder recurrence. In 6 of the 8 patients, pre-operatural examination revealed concomitant bladder cancer without and 2 cases with muscle inﬁltration. Five of the 6 patients with concomitant bladder cancer and without muscle inﬁltration were treated by transurethral resection without additional chemo- or radiation therapy;the latter 2 patients with muscle inﬁltration underwent radical cysto-
urethrectomy. The remaining patient underwent cysto-
urethrectomy for multiple tumor recurrence, although no obvious sub-mucosal invasion had been observed before surgery. Histo-pathological ﬁndings in the urethrectomy specimens of these 3 patients revealed micro-invasion into the prostate and/or into the deep muscle wall. After additional adjuvant systemic chemotherapy was performed on these 3 patients, 2 patients showed no evidence of recurrence, and one died of the cancer 2 months after the surgery. Malignant progression (3 patients with local invasive recurrence and 1 patient with a distant metas-
tasis)was revealed during the follow-up treatment period as described above. Thus, Malignant progression was observed in 4 of the 5 patients who were treated conserva-
tively, 9 to 37 months after the transurethral manage-
ment. These 4 patients received intensive therapy, includ-
ing radical cysto-urethrectomy and systemic chemother-
apy. However, each patient had a poor prognosis and died within 1 year. Transurethral management succeeded in controlling the disease in only one patient with anterior urethral recurrence. The summaries and clinical courses of these 8 cases are shown in Table 3.
On the other hand, among the ﬁve cases involving progression without urethral recurrence, had lymph node metastasis with local progression, two had distant metas-




Numerous factors that are prognostic of superﬁcial bladder cancer have been reported for use as markers.
However, there is no deﬁnite marker for determining the treatment of superﬁcial bladder cancer. Recent advances in molecular biological techniques have revealed many factors such as oncogenes and onco-supressor genes that may aﬀect the clinical course of superﬁcial bladder cancer.
Intensive studies have shown that among the several identiﬁed prognostic markers, the status of suppressor gene p53 mutation, the Ki-67 labeling index, and EGFr are very useful. Detection of malignant phenotypes,
especially those related to local invasion and metastasis,
are the major subjects of cancer research. However, the suggested impact of these factors (e.g., prognostic molecular markers, tumor number, tumor size, tumor grade, and CIS varies among reports［1-6］. Moreover,
there have been no deﬁnitive clinical evaluations to date,
and it remains diﬃcult to predict global clinical courses according to minute molecular biological changes. In addition, the standard treatment strategy for patients with concomitant CIS diﬀers from that for patients without
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Table 2  Univariate and multivariate analysis of recurrent cases (n＝149)
Factors  Category  Univariate P-Value  
Multivariate P-Value
 
Urethral Tumor (－)/(＋) 0.0008?? 0.017?
Tumor Number  1/2-4/5＜ 0.764  0.492 Tumor Size ＜l/1-3/3＜ 0.738  0.859 Tumor Shape  Stalk/Broadbased/Non-Pap. 0.032? 0.433 Neck Tumor (－)/(＋) 0.577  0.887 Grade  1/2/3  0.006?? 0.094 Stage  Ta/Tl  0.012? 0.191
?P＜0.05, ??P＜0.01.
Analyses are based on accumulated characteristics evaluated by Cox’s Proportional Hazards Model.
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 concomitant CIS. Our results suggest that anterior urethral recurrence following superﬁcial bladder cancer is a signiﬁcant predictor of malignant progression. Although some clinical reports［7-12］have described urethral recurrence after cystectomy for advanced bladder cancer,
as well as the occurrence of primary anterior urethral cancer, there have been few clinical studies on urethral recurrence following superﬁcial bladder cancer. Erckert et al.［12］reported the clinical features of urethral tumor involvement in 910 male patients with bladder cancer at all stages;although the patient number is large,
the criteria for urethral recurrence included both the anterior and posterior urethra, without distinguishing between the 2 types of tumor. Our retrospective study is one of the few that deal speciﬁcally with the clinical signiﬁcance of anterior urethral recurrence following superﬁcial bladder cancer.
It has been a long-term matter of debate whether such metachronous tumors represent the unrecognized direct extension of bladder cancer, the seeding of cancer cells from the bladder, metastasis, or a second manifestation of a multicentric defect of the transitional cell mucosa that caused the original bladder cancer. Freeman et al.［9］
supported the latter theory in cases of post-radical cystectomy, since urethral tumors occur variably through-
out the length of the anterior urethra as skip lesions and in the absence of a positive surgical margin. The results of that study did not support the theory of mechanical implantation, since urethral tumors tend not to occur in areas of stricture, which presumably represent sites of mucosal trauma and thus the most fertile ground for seeding. If this speculation is true across the board,
conservative treatment may be feasible, provided the tumor is superﬁcial. However, such speculation is based on the results of urethral recurrence after radical cystectomy. It is important to consider the circumstance in which continuous urinary ﬂow from upstream lesions may contain cancer cells that are then transported to the urethra. These conditions diﬀer radically from those of a post-radical cystectomy, in which mechanical implantation from a superﬁcial bladder cancer seems primary. Mechan-
ical implantation may lead to more invasive tumors of the anterior urethra than would be expected among second-
manifestation tumors due to multicentric defects of the transitional cell mucosa;this would be the case because the injured urethral mucosa into which the cancer cells are implanted is thin, as is the muscle wall, and is adjacent to cavernous tissue with abundant blood ﬂow. Cancer cells may easily migrate into the blood stream and cause distant metastasis in such circumstances. In fact, histo-
pathological examination of our patients with urethral recurrence who had undergone radical cysto-urethrectomy immediately revealed micro-invasion to deep sites, and 4 of the 5 patients who were treated conservatively for anterior urethral recurrences had poor prognoses. These ﬁndings indicate the potent ability of cancer cells to migrate and eventually form local invasions and distant metastases at the time of anterior urethral recurrence.
Since urethral recurrence of superﬁcial bladder cancer can be regarded as a sign of the high malignancy of cancer cells, immediate radical and systematic therapy, including cysto-urethrectomy, chemotherapy, or radiation therapy,
should be performed as soon as recurrence is diagnosed.
To prevent tumor seeding, the urethral mucosa should be
 
Table 3  Detailed clinical features of patients with anterior urethral recurrence
 
Frequency before urethral recurrence
 
Period from onset to urethral recurrence
(months)
Treatment for urethral recurrence
 
Pathological bladder ﬁndings at urethral recurrence
 
Period from urethral recurrence to progression
(months)
Treatment after progression  
Prognosis
 
Survival duration after urethral recurrence
 
Survival duration after progression
 
1  3  40  TUR  T1,G3  9  Radical  Dead  17  8 2  2  18  TUR  T1,G2  37  Radical  Dead  49  12 3  4  55  TUR  T1,G2  31  In-ope. Dead  34  3 4  4  76  TUR  Ta,G3  10  Radical  Dead  11  1 5  11  148  TUR  Ta,G2  No progression  Alive  51 6  6  80  Radical  T3b,G2  Synchronous  Alive  12  12 7  1  14  Radical  T4,G3  Synchronous  Dead  2  2 8  4  21  Radical  T1,G3  No progression  Alive  108
 
Radical,radical cysto-urethrectomy.
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protected during any transurethral maneuver. Although this was not a randomized prospective study, the follow-
ing conclusions can be drawn from the present results:1］
anterior urethral recurrence of superﬁcial bladder cancer could be a signiﬁcant prognostic factor;2］immediate radical systematic intensive therapy should be performed in such cases;3］ precise urethroscopic examination should also be performed during the routine follow-up treatment for superﬁcial bladder cancer.
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